Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JP Morgan Maintains Overweight on Amrize, Raises Price Target to $60

Author: Benzinga Newsdesk | August 26, 2025 10:06am
JP Morgan analyst Adrian Huerta maintains Amrize (NYSE:AMRZ) with a Overweight and raises the price target from $52 to $60.

Posted In: AMRZ

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist